TE VA 7630 (Imatinib mesylate 400 mg)
Pill imprint TE VA 7630 has been identified as Imatinib mesylate 400 mg.
Imatinib is used in the treatment of chronic myelogenous leukemia; gastrointestinal stromal tumor; acute lymphoblastic leukemia; chronic eosinophilic leukemia; dermatofibrosarcoma protuberans (and more), and belongs to the drug class BCR-ABL tyrosine kinase inhibitors. There is positive evidence of human fetal risk during pregnancy. Imatinib 400 mg is not a controlled substance under the Controlled Substance Act (CSA).
- Imprint:
- TE VA 7630
- Strength:
- 400 mg
- Color:
- Brown
- Shape:
- Capsule-shape
- Availability:
- Prescription only
- Drug Class:
- BCR-ABL tyrosine kinase inhibitors
- Pregnancy Category:
- D - Positive evidence of risk
- CSA Schedule:
- Not a controlled drug
- Manufacturer:
- Teva Pharmaceuticals USA, Inc.
More about imatinib
Consumer resources
- Other brands: Gleevec
Professional resources
Related treatment guides
Disclaimer:
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.
